

Orfadin, Nityr [nitisinone]

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: Patient's ID: Physician's Name: Specialty:		Date:Patient's Date of Birth: NPI#:			
			Ph	ysician Office Telephone:	Physician Office Fax:
			Re	equest Initiated For:	
1.	What is the diagnosis? ☐ Hereditary tyrosinemia type 1 (HT-1) ☐ Other				
2.	What is the ICD-10 code?				
3.	The preferred product for your patient's health plan is Orfadin. Can the patient's treatment be switched to the preferred product. If Yes, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017. \[\textstyle{\textsty				
4.	Does the patient have a documented intolerable adverse event with the preferred product (Orfadin) that was not an expected adverse event attributed to the active ingredient as described in the prescribing information? <i>ACTION REQUIRED: If Yes, attach supporting chart notes.</i> \square Yes \square No				
5.	Was the diagnosis confirmed by a biochemical testitesting? ACTION REQUIRED: If Yes, attach supp	ng (e.g., detection of succinylacetone in urine) or DNA porting chart note(s). \square Yes \square No			
6.	Is this request for continuation of therapy with nitis	inone (Orfadin, Nityr)? If Yes, skip to #8 🗖 Yes 🗖 No			
7.	Is the requested medication being used as an adjuncular of Yes □ No No further questions.	t to dietary restriction of tyrosine and phenylalanine?			
8.	Is the patient experiencing beneficial clinical respon	se from therapy? ☐ Yes ☐ No			
	uttest that this information is accurate and true, formation is available for review if requested by				
X _					
Prescriber or Authorized Signature		Date (mm/dd/yy)			

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization. Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orfadin, Nityr [nitisinone] VF, ACSF SGM - 1/2023.